This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

被引：0

作者：

Dimopoulos, M. A. ^{[1
]}

Oriol, A. ^{[2
]}

Nahi, H. ^{[3
,4
]}

Miguel, J. S. ^{[5
]}

Bahlis, N. J. ^{[6
]}

Rabin, N. ^{[7
]}

Orlowski, R. ^{[8
]}

Komarnicki, M. ^{[9
]}

Suzuki, K. ^{[10
]}

Plesner, T. ^{[11
,12
]}

Samoilova, O. S. ^{[13
]}

Yoon, S. S. ^{[14
]}

Yehuda, D. B. ^{[15
]}

Richardson, P. G. ^{[16
]}

Goldschmidt, H. ^{[17
,18
]}

Reece, D. ^{[19
]}

Khokhar, N. ^{[20
]}

O'Rourke, L. ^{[20
]}

Chiu, C. ^{[20
]}

Qin, X. ^{[21
]}

Guckert, M. ^{[20
]}

Ahmadi, T. ^{[20
]}

Moreau, P. ^{[22
]}

机构：

[1] Univ Athens, Athens, Greece

[2] HGTiP, Inst Catala Oncol, Barcelona, Spain

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[5] Univ Navarra Clin, CIMA, Pamplona, Spain

[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[9] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland

[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[11] Vejle Hosp, Vejle, Denmark

[12] Univ Southern Denmark, Vejle, Denmark

[13] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[14] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[15] Hadassah Hebrew Univ Med Ctr, Hematol Dept, Jerusalem, Israel

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[17] Univ Hosp Heidelberg, Heidelberg, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] Princess Margaret Canc Ctr, CCRU, Toronto, ON, Canada

[20] Janssen Res & Dev, Spring House, PA USA

[21] Janssen Res & Dev, Horsham, PA USA

[22] Univ Hosp Hotel Dieu, Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB2238

引用

页码：342 / 342

页数：1

共 50 条

[31] Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial [J].

Siegel, David S. ;

Schiller, Gary J. ;

Samaras, Christy J. ;

Sebag, Michael ;

Berdeja, Jesus G. ;

Ganguly, Siddhartha ;

Matous, Jeffrey V. ;

Song, Kevin W. ;

Seet, Christopher S. ;

Acosta-Rivera, Mirelis ;

Bar, Michael ;

Quick, Donald P. ;

Anz, Bertrand M., III ;

Fonseca, Gustavo A. ;

Reece, Donna E. ;

Lee, Kim ;

Chung, Weiyuan ;

Agarwal, Amit ;

Bahlis, Nizar J. .

BLOOD, 2020, 136

[32] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial [J].

Plesner, Torben ;

Dimopoulos, Meletios A. ;

Oriol, Albert ;

San-Miguel, Jesus ;

Bahlis, Nizar J. ;

Rabin, Neil ;

Suzuki, Kenshi ;

Yoon, Sung-Soo ;

Ben-Yehuda, Dina ;

Cook, Gordon ;

Goldschmidt, Hartmut ;

Grosicki, Sebastian ;

Qin, Xiang ;

Fastenau, John ;

Garvin, Wendy ;

Carson, Robin ;

Renaud, Thomas ;

Gries, Katharine S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) :132-139

[33] Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study [J].

Stewart, A. Keith ;

Rajkumar, S. Vincent ;

Dimopoulos, Meletios A. ;

Masszi, Tamas ;

Spicka, Ivan ;

Oriol, Albert ;

Hajek, Roman ;

Rosinol, Laura ;

Siegel, David S. ;

Mihaylov, Georgi G. ;

Goranova-Marinova, Veselina ;

Rajnics, Peter ;

Suvorov, Aleksandr ;

Niesvizky, Ruben ;

Jakubowiak, Andrzej ;

San Miguel, Jesus F. ;

Ludwig, Heinz ;

Zojwalla, Naseem ;

Tonda, Margaret E. ;

Xing, Biao ;

Moreau, Philippe ;

Palumbo, Antonio .

BLOOD, 2014, 124 (21)

[34] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience [J].

Moustafa, Muhamad Alhaj ;

Parrondo, Ricardo ;

Abdulazeez, Mays F. ;

Roy, Vivek ;

Sher, Taimur ;

Alegria, Victoria R. ;

Warsame, Rahma M. ;

Larsen, Jeremy ;

Gonsalves, Wilson I. ;

Kourelis, Taxiarchis ;

Kapoor, Prashant ;

Fonseca, Rafael ;

Buadi, Francis K. ;

Dingli, David ;

Hayman, Suzanne R. ;

Reeder, Craig B. ;

Agrawal, Arshi ;

Chanan-Khan, Asher A. ;

Ailawadhi, Sikander .

BLOOD, 2020, 136

[35] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA [J].

Dimopoulos, M. ;

Lonial, S. ;

Palumbo, A. ;

White, D. ;

Grosicki, S. ;

Spicka, I. ;

Walter-Croneck, A. ;

Moreau, P. ;

Mateos, M. -V. ;

Magen, H. ;

Belch, A. ;

Reece, D. ;

Beksac, M. ;

Spencer, A. ;

Oakervee, H. ;

Taniwaki, M. ;

Roellig, C. ;

Wu, K. L. ;

Singhal, A. ;

San Miguel, J. ;

Matsumoto, M. ;

Katz, J. ;

Bleickardt, E. ;

Poulart, V. ;

Richardson, P. .

HAEMATOLOGICA, 2015, 100 :173-173

[36] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial [J].

Stewart, A. Keith ;

Siegel, David ;

Ludwig, Heinz ;

Facon, Thierry ;

Goldschmidt, Hartmut ;

Jakubowiak, Andrzej J. ;

Miguel, Jesus F. San ;

Obreja, Mihaela ;

Blaedel, Julie ;

Dimopoulos, Meletios A. .

BLOOD, 2017, 130

[37] Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux [J].

Moreau, Philippe ;

Kaufman, Jonathan L. ;

Sutherland, Heather J. ;

Lalancette, Marc ;

Magen, Hila ;

Iida, Shinsuke ;

Kim, Jin Seok ;

Prince, Miles ;

Cochrane, Tara ;

Khokhar, Nushmia Z. ;

Guckert, Mary ;

Qin, Xiang ;

Oriol, Albert .

BLOOD, 2016, 128 (22)

[38] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma [J].

Shinsuke Iida ;

Tohru Izumi ;

Takuya Komeno ;

Yasuhito Terui ;

Takaaki Chou ;

Takashi Ikeda ;

Deborah Berg ;

Shinichi Fukunaga ;

Kenkichi Sugiura ;

Makoto Sasaki .

International Journal of Clinical Oncology, 2022, 27 :224-233

[39] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma [J].

Iida, Shinsuke ;

Izumi, Tohru ;

Komeno, Takuya ;

Terui, Yasuhito ;

Chou, Takaaki ;

Ikeda, Takashi ;

Berg, Deborah ;

Fukunaga, Shinichi ;

Sugiura, Kenkichi ;

Sasaki, Makoto .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) :224-233

[40] A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). [J].

Delimpasi, Sosana ;

Pour, Ludek ;

Auner, Holger W. ;

Dimopoulos, Meletios A. ;

Rappaport, Alon ;

Fortin, Lisa ;

Shah, Jatin J. ;

Shacham, Sharon ;

Kauffman, Michael G. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →